University of Oulu

Korkeila, E.A., Salminen, T., Kallio, R. et al. Support Care Cancer (2017) 25: 2771. https://doi.org/10.1007/s00520-017-3689-5

Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer

Saved in:
Author: Korkeila, Eija1; Salminen, T.2; Kallio, Raija3;
Organizations: 1Department of Oncology, University of Turku and Turku University Hospital
2Department of Oncology, Tampere University and Tampere University Hospital
3Department of Oncology and Haematology, Oulu University and Oulu University Hospital
4Department of Oncology, Vaasa Central Hospital
5Faculty of Medicine and Cancer Center and Department of Oncology, University of Eastern Finland, Kuopio University Hospital
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.5 MB)
Persistent link: http://urn.fi/urn:nbn:fi-fe201708308266
Language: English
Published: Springer Verlag, 2017
Publish Date: 2017-08-30
Description:

Abstract

Purpose: This study aimed to evaluate the feasibility and tolerability of biweekly docetaxel with capecitabine as first-line treatment in advanced gastro-oesophageal cancer.

Methods: Fifty-three patients at median age of 61 years with advanced gastric cancer were included in this prospective, non-randomized, multicentre phase II trial to receive intravenous docetaxel 50 mg/m2 on days 1 and 15, and oral capecitabine 1250 mg/m2 every 12 h, on days 1–7 and 15–21 of each 28-day cycle. QOL was assessed using EORTC QLQ-C30, together with the gastric module (QLQ-STO 22).

Results: Forty-six patients were evaluable for QOL analyses. No deterioration in global health status was found. Social functioning scores improved, and eating difficulties and pain were alleviated during treatment. The most common grade 3 or 4 toxicity was neutropenia (47%), whereas neutropenic fever was uncommon (6%). The clinical benefit rate was 60%, including complete and partial responses as well as stabilized disease. Median overall survival was 8.8 months (95% CI 5.8–11.9 months), and median time to progression was 6.2 months (95% CI 4.9–7.5 months).

Conclusions: Biweekly docetaxel with capecitabine is a feasible treatment in AGC, delivered on an outpatient basis, with no need for central venous access device. No deterioration of global health status was reported. In addition, pain and eating difficulties were alleviated during study treatment. This trial is registered at ClinicalTrials.gov, number NCT00669370.

see all

Series: Supportive care in cancer
ISSN: 0941-4355
ISSN-E: 1433-7339
ISSN-L: 0941-4355
Volume: 25
Issue: 9
Pages: 2771 - 2777
DOI: 10.1007/s00520-017-3689-5
OADOI: https://oadoi.org/10.1007/s00520-017-3689-5
Type of Publication: A1 Journal article – refereed
Field of Science: 3122 Cancers
Subjects:
Funding: This study was partly supported by a grant from Sanofi Genzyme.
Copyright information: © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
  https://creativecommons.org/licenses/by/4.0/